search
Back to results

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

Primary Purpose

Pneumonia, Pneumocystis Carinii, HIV Infections

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Atovaquone
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pneumonia, Pneumocystis Carinii focused on measuring Pneumonia, Pneumocystis carinii, Antifungal Agents, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Biological Availability, atovaquone

Eligibility Criteria

1 Month - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). Dideoxycytidine (zalcitabine; ddC). Didanosine (ddI). Nonaminoglycoside, nonmacrolide, and nonsulfonamide antibiotics. Factor VIII. IVIG. Patients must have: AIDS, documented HIV infection, perinatal exposure to HIV, or risk of developing PCP. Normal EKG and chest radiograph. No blood or protein on urinalysis. Consent of parent or guardian. Prior Medication: Allowed: Prophylactic TMP/SMX if given no less than 3 days prior to study entry. Prophylactic aerosolized pentamidine (or a single intravenous dose of 4.0 mg/kg pentamidine) if given no less than 7 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Anticipated organ system or laboratory abnormalities (other than immune system abnormalities) from the primary disease and its treatment during the study. Acute or chronic infections requiring treatment during the study. NOTE: Thrush and herpes labialis are allowed if these conditions do not require treatment. Diarrhea or vomiting. Concurrent Medication: Excluded: Trimethoprim/sulfamethoxazole. Sulfadoxine and pyrimethamine (Fansidar). Primaquine. Aspirin. Amphotericin B. Aminoglycoside antibiotics. Sulfonamides. Dapsone. Benzodiazepines. Rifampin. Erythromycin, clarithromycin, and azithromycin. Digitalis. Para-aminosalicylic acid (PAS). Isoniazid. Anticoagulants. Any other investigational therapies. Patients with the following prior condition are excluded: History of G6PD deficiency.

Sites / Locations

  • UCSF Pediatric AIDS CRS
  • Chicago Children's CRS
  • Tulane/LSU Maternal/Child CRS
  • DUMC Ped. CRS
  • St. Jude/UTHSC CRS
  • Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
October 27, 2021
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT00000773
Brief Title
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
Official Title
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 1996 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

5. Study Description

Brief Summary
To determine the safety, tolerance, and pharmacokinetics of a new improved microparticulate suspension formulation of atovaquone administered at one of two dose levels (per 09/30/94 amendment, a third dose level was added) daily for 12 days in HIV-infected and perinatally exposed (per 8/9/95 amendment) infants and children who are at risk of developing Pneumocystis carinii pneumonia (PCP). Atovaquone has shown prophylactic potential in adults in the treatment of PCP but is poorly absorbed in tablet form. To improve the bioavailability of atovaquone, a new formulation has been prepared as a microparticulate suspension. Since studies in adults have demonstrated substantial safety of this drug, evaluation in children is being pursued.
Detailed Description
Atovaquone has shown prophylactic potential in adults in the treatment of PCP but is poorly absorbed in tablet form. To improve the bioavailability of atovaquone, a new formulation has been prepared as a microparticulate suspension. Since studies in adults have demonstrated substantial safety of this drug, evaluation in children is being pursued. Three cohorts of four patients each (ages 2-12 years, 3 months to less than 2 years, and 1 month to less than 3 months) receive atovaquone daily for 12 days. The oldest age group is treated first. In the absence of unacceptable toxicity, the dose of atovaquone is escalated in subsequent 4-patient cohorts representing each of the age stratifications and (per 9/30/94 amendment) in a separate 4-patient cohort aged 3 months to less than 2 years. If two of four patients in a given cohort experience unacceptable toxicity at the initial dose, two additional patients in the same age range are entered. Blood samples are drawn for pharmacokinetic evaluation. Patients are followed to day 24. Per 9/30/94 amendment, patients aged 3 months to less than 2 years of age who received one of the lower doses may re-enroll in the higher dose cohort after a 1-month washout.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia, Pneumocystis Carinii, HIV Infections
Keywords
Pneumonia, Pneumocystis carinii, Antifungal Agents, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Biological Availability, atovaquone

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Masking
None (Open Label)
Enrollment
24 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Atovaquone

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). Dideoxycytidine (zalcitabine; ddC). Didanosine (ddI). Nonaminoglycoside, nonmacrolide, and nonsulfonamide antibiotics. Factor VIII. IVIG. Patients must have: AIDS, documented HIV infection, perinatal exposure to HIV, or risk of developing PCP. Normal EKG and chest radiograph. No blood or protein on urinalysis. Consent of parent or guardian. Prior Medication: Allowed: Prophylactic TMP/SMX if given no less than 3 days prior to study entry. Prophylactic aerosolized pentamidine (or a single intravenous dose of 4.0 mg/kg pentamidine) if given no less than 7 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Anticipated organ system or laboratory abnormalities (other than immune system abnormalities) from the primary disease and its treatment during the study. Acute or chronic infections requiring treatment during the study. NOTE: Thrush and herpes labialis are allowed if these conditions do not require treatment. Diarrhea or vomiting. Concurrent Medication: Excluded: Trimethoprim/sulfamethoxazole. Sulfadoxine and pyrimethamine (Fansidar). Primaquine. Aspirin. Amphotericin B. Aminoglycoside antibiotics. Sulfonamides. Dapsone. Benzodiazepines. Rifampin. Erythromycin, clarithromycin, and azithromycin. Digitalis. Para-aminosalicylic acid (PAS). Isoniazid. Anticoagulants. Any other investigational therapies. Patients with the following prior condition are excluded: History of G6PD deficiency.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hughes W
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Dorenbaum A
Official's Role
Study Chair
Facility Information:
Facility Name
UCSF Pediatric AIDS CRS
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Chicago Children's CRS
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60614
Country
United States
Facility Name
Tulane/LSU Maternal/Child CRS
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
DUMC Ped. CRS
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
St. Jude/UTHSC CRS
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
City
San Juan
ZIP/Postal Code
00936
Country
Puerto Rico

12. IPD Sharing Statement

Citations:
Citation
Dorenbaum A, Sadler BM, Xu J, Van Dyke RB, Wei LJ, Moye J, McNamara J, Yogev R, Diaz C, Hughes W. Phase I safety and pharmacokinetics (PK) study of micronized atovaquone (m-ATQ) in HIV exposed or infected infants and children. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:117 (abstract no 288)
Results Reference
background

Learn more about this trial

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

We'll reach out to this number within 24 hrs